Inflammatory Bowel Disease Clinical Trial
Official title:
Perianal Fistula Procedure Validation, Matched Case Control, and Patient Journey Study
Verified date | March 2021 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to gain a better understanding of the disease burden and unmet need of perianal fistulas within Crohn's disease (CD) in Ontario.
Status | Completed |
Enrollment | 3032 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 17, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 105 Years |
Eligibility | Inclusion Criteria for Objective 1: 1. Inclusion in the TOH "reference" database. 2. Aged 18-105 inclusive at date of index. 3. Participant can be linked between TOH "reference" database to the Institute for Clinical Evaluative Sciences (ICES) databases based on health card number. 4. Incident inclusion in the Ontario Crohn's and Colitis Cohort (OCCC) between April 1, 2002 to July 1, 2013. 5. Incident diagnosis of CPAF in TOH database between April 1, 2004 to July 1, 2015. Inclusion Criteria for Objective 2: 1. Participants were incident in the OCCC from April 1, 2002 to March 31, 2012. 2. The case meets the PAF case definition identified in Objective 1 in the selection period (April 1, 2005 to March 31, 2012). 3. Aged 18-105 inclusive at date of index. Inclusion Criteria for Objective 3: 1. Inclusion in the OCCC at or prior to index visit with a diagnosis of Crohn's disease. 2. The case meets the CPAF case definition identified in Objective 1 in the selection period. 3. Have to have 5 years of follow-up. 4. Aged 18-105 inclusive at date of index. Exclusion Criteria for Objective 1: 1. Missing demographics at index date (sex, age, Local Health Integration Network (LHIN), income quintile) in all databases. 2. Death date in the ICES data prior to TOH CPAF incidence date. Exclusion Criteria for Objective 2: 1. Missing demographics at index date (sex, age, neighbourhood income quintile, LHIN). 2. Death during 5-year analysis period. 3. Ontario Health Insurance Plan (OHIP) coverage is terminated during the follow-up example if the participant moves to another province. 4. Meeting the case definition during the lookback period. 5. Cases for whom a matched control cannot be found. Exclusion Criteria for Objective 3: 1. Missing demographics at index date (sex, age, neighbourhood income quintile, LHIN). 2. Death during 5-year analysis period. 3. OHIP coverage is terminated during the 5-year analysis period example if the participant moves to another province. 4. Meeting the case definition during the lookback period. |
Country | Name | City | State |
---|---|---|---|
Canada | Takeda Canada | Oakville | Ontario |
Lead Sponsor | Collaborator |
---|---|
Takeda |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective 1: Number of CD Participants Who Have CPAF Using Various Codes in an TOH Database | Index date first time participant meets case definition(diagnosis of CD with CPAF in index period).Participants divided as:2 diagnosis/imaging codes(IC),2 codes must be in 2 year(yr) period of each other;3 diagnosis/IC/intervention code/EUA+seton;3 diagnosis/IC/intervention code/EUA+seton,diagnosis/IC requirements are satisfied,codes must be in 2yr period of each other;2 diagnosis/IC;3 diagnosis/IC,3 codes must be in 2yr period of each other;3 diagnosis/IC;diagnosis/IC+(EUA+Seton);diagnosis/IC+(EUA+Seton),2 codes must be in 2yr period of each other;3 diagnosis /IC+intervention code 4 codes must be in 2 yr period of each other;2 IC/intervention code/diagnosis code/EUA+seton;2 IC/intervention code/diagnosis code/EUA+seton,IC requirements are satisfied, codes must be in 2yr period of each other;2 diagnosis/IC+intervention code;3 diagnosis/IC+intervention code;2 diagnosis/IC+intervention code,3 codes must be in 2yr period of each other;diagnosis/imaging/intervention codes;diagnosis/IC. | From the date of CD diagnosis up to the index date (approximately 5 years) | |
Primary | Objective 2: Mean Costs for Crohn's Disease Participants With and Without CPAF in ICES Database CPAF | Impact of total disease burden on participants CD with and without CPAF was measured as total cost and cost by sector which included general physicians (GP), specialist, all physician OHIP, home care services, hospital admissions, dialysis, cancer, and radiation, emergency department (ED), Ontario drug benefit (ODB), hospital outpatient clinics, same day surgery (SDS). Index date was defined as the date the first time the participant meets the case definition i.e. diagnosis of CD with CPAF in the index period. | From the index date up to end of study (approximately 5 years post-index) | |
Primary | Objective 2: Number of Visits for Healthcare Resource Utilization for Crohn's Disease Participants With and Without CPAF in ICES Database | Healthcare Resource Utilization was based on three procedures which included the number of ED visits, number of hospitalizations and number of outpatient visits. Index date was defined as the date the first time the participant meets the case definition i.e. diagnosis of CD with CPAF in the index period. | From the index date up to end of study (approximately 5 years post-index) | |
Primary | Objective 3: Mean Costs Based on Three Procedures for Crohn's Disease Participants With CPAF by Sector in ICES Database | Impact of total disease burden on participants CD with CPAF was based on three procedures which included total cost, total cost (without ODB) and cost by sector i.e. general physicians (GP), specialist, all physician OHIP, home care services, hospital admissions, Dialysis, Cancer, and Radiation, non-hospital based residential care, emergency department (ED), Ontario drug benefit (ODB), hospital outpatient clinics, same day surgery (SDS). Index date was defined as the date the first time the participant meets the case definition i.e. diagnosis of CD with CPAF in the index period. Participants with CD and CPAF were categorized into pre-defined treatment pathways and results are reported in three arms: No Intervention, EUA ± Seton and Advanced Intervention. | From the index date up to 5 years post-index | |
Primary | Objective 3: Number of Visits for Healthcare Resource Utilization Based on Three Procedures for Crohn's Disease Participants With CPAF | Healthcare Resource Utilization was based on three procedures which included the number of ED visits, number of hospitalizations and number of outpatient visits. Index date was defined as the date the first time the participant meets the case definition i.e. diagnosis of CD with CPAF in the index period. Participants with CD and CPAF were categorized into pre-defined treatment pathways and results are reported in three arms: No Intervention, EUA ± Seton and Advanced Intervention. | From the index date up to 5 years post-index |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03278912 -
Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
|
||
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05579392 -
A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
|
N/A | |
Completed |
NCT03264690 -
Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
|
||
Recruiting |
NCT02861053 -
Inflammatory Bowel Disease : Could a Regular Physical Activity Reduce Patients Fatigue ?
|
N/A | |
Recruiting |
NCT02275676 -
Resting Energy Expenditure and Nutritional Status in IBD
|
N/A | |
Completed |
NCT02161640 -
Vascular Dysfunction in Paediatric IBD
|
N/A | |
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT01860651 -
Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT01852760 -
Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound
|
N/A | |
Completed |
NCT01933867 -
Water-aided Colonoscopy in Inflammatory Bowel Disease Patients
|
N/A | |
Completed |
NCT01688557 -
Trial on Innovative Technologies in Colonoscopy
|
N/A | |
Completed |
NCT01692743 -
Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
|
Phase 3 | |
Completed |
NCT01666535 -
Infliximab IBD Influenza Vaccine Study
|
N/A | |
Completed |
NCT01676324 -
FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT01981616 -
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
|
Phase 1 | |
Completed |
NCT01557387 -
Real-time Diagnosis of Pseudopolyps During Colonoscopy
|
||
Completed |
NCT01221818 -
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A |